论文部分内容阅读
目的探讨利福喷丁以及利福平治疗肺结核患者的效果以及安全性。方法选取吉林市结核病医院2015年6月至2017年1月收治的90例肺结核患者,两组患者均服用异烟肼、吡嗪酰胺以及乙胺丁醇治疗,将其随机分为观察组以及对照组,分别应用利福喷丁以及利福平治疗,比较两组患者的痰涂片转阴率、空洞闭合情况以及不良反应情况。结果观察组患者在治疗3、5、6个月末的痰转阴率均明显高于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗后病灶的总改善率为91.1%,明显高于对照组的66.7%,差异有统计学意义(P<0.05);观察组患者不良反应发生率为17.8%,明显低于对照组的62.2%,差异有统计学意义(P<0.05)。结论利福喷丁治疗肺结核具有高效、低毒等优点,是治疗肺结核的理想方法。
Objective To investigate the efficacy and safety of rifapentine and rifampin in the treatment of patients with pulmonary tuberculosis. Methods Ninety patients with tuberculosis who were admitted to Jilin Tuberculosis Hospital from June 2015 to January 2017 were treated with isoniazid, pyrazinamide and ethambutol, and were randomly divided into observation group and control group Group, respectively, the application of rifapentine and rifampicin treatment, two groups of patients sputum smear negative conversion rates, hollow closure and adverse reactions. Results The sputum negative conversion rate in the observation group was significantly higher than that in the control group at the end of 3, 5 and 6 months (all P <0.05). The total improvement rate of the observation group after treatment was 91.1 %, Which was significantly higher than that of the control group (66.7%, P <0.05). The incidence of adverse reactions in the observation group was 17.8%, which was significantly lower than that in the control group (62.2%, P < 0.05). Conclusions Rifampicin treatment of tuberculosis has the advantages of high efficiency, low toxicity and is an ideal method for the treatment of pulmonary tuberculosis.